Valeant vows to refute 'phantom sales' allegations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/4/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. GWRE
10. CIEN

Go back to Valeant vows to refute 'phantom sales' allegations

Endo Int'l (ENDP), BioDelivery Sciences (BDSI) Announce FDA Approval of BELBUCA as Chronic Pain Treatment

October 26, 2015 6:26 AM EDT

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI), announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA, which is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management, is... More

Horizon Pharma (HZNP) Issues Statement to Correct 'Misinformation in the Marketplace'

October 22, 2015 5:41 PM EDT

Horizon Pharma (NASDAQ: HZNP) today provided the following statement to correct misinformation in the marketplace:

Horizon takes seriously its responsibility to ensure patients have access to our medicines. Horizon enhances patients' access through several programs, one of which ensures that patients have a low out-of-pocket cost for Horizon medicines. This has... More